The Gene Therapy in Oncology Market is expanding rapidly as gene editing technologies, oncolytic viruses, and gene transfer approaches reshape the landscape of cancer treatment. Within the broader cancer gene therapy market, oncology-focused gene therapies are projected to grow from a multibillion-dollar base in the mid-2020s to tens of billions by 2035, driven by strong pipelines and increasing regulatory approvals. Forecasts for the cancer gene therapy space point to robust double-digit CAGRs through 2035.

Gene therapy in oncology encompasses several strategies: delivering therapeutic genes to tumor cells, editing cancer-related genes, using oncolytic viruses that selectively infect and kill cancer cells, and modulating the immune system (e.g., via gene-modified immune cells). These approaches aim to directly attack tumor cells, sensitize them to other treatments, or enhance antitumor immunity. Ex vivo and in vivo gene therapies, delivered via viral vectors, plasmids, or nanoparticle systems, form the core technical modalities.

Growth is fueled by advances in gene editing (such as CRISPR/Cas systems), better vector design, and improved understanding of tumor genetics. Clinical success in hematologic malignancies and early signals in solid tumors are attracting substantial investment from pharma, biotech, and venture capital. Regulatory agencies are establishing clearer pathways for gene therapy approval, though long-term safety, manufacturing complexity, and cost remain key challenges.

FAQs
Q1. What kinds of gene therapies are used in oncology?
Gene transfer, gene editing, oncolytic virus therapy, gene silencing, and immune-modulating gene therapies.

Q2. What drives this market’s growth?
Technological advances in gene editing and vectors, strong clinical results in select cancers, and high unmet need for more effective treatments.

Tags: gene therapy in oncology, cancer gene therapy, oncolytic viruses, gene editing, ex vivo therapy, in vivo gene delivery, targeted cancer treatment